ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of the FlexAbility™ Ablation Catheter, a new ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias. Designed with feedback from leaders in the electrophysiology community, the FlexAbility catheter combines a bendable irrigated catheter tip with an advanced handle and next generation shaft design. The unique flexible tip was developed to conform better to the cardiac anatomy, allowing for effective lesion formation. This added flexibility, in addition to the catheter’s ability to maneuver easily and reliably in challenging cases, was designed to enhance the quality of care for patients around the world who require ablation procedures.
“The FlexAbility catheter is the only ablation catheter with a flexible tip available to electrophysiologists in the United States today,” said Dr. Andrea Natale, executive medical director at the Texas Cardiac Arrhythmia Institute. “For the past several years we’ve been looking for a catheter that provided a gentler, more optimal approach to ablation. The FlexAbility catheter addresses this need and provides me with another safe treatment option for my patients.”
Ablation catheters, such as the pioneering FlexAbility catheter, are thin, flexible wires used to help treat irregular heartbeats that impair the heart’s ability to effectively pump blood throughout the body. In the U.S., an estimated 10.4 million people have some type of cardiac arrhythmia. The FlexAbility catheter features an innovative handle and shaft combination that allows for improved maneuverability, enabling electrophysiologists to reach challenging anatomic locations within their patients’ hearts. This new technology was also designed to provide optimal irrigation flow over the entire tip for improved cooling, potentially reducing risk factors associated with the delivery of therapy.
“As we developed the FlexAbility ablation catheter, we worked with leading electrophysiologists to ensure this ablation technology would advance the treatment of complex arrhythmias,” said Srijoy Mahapatra, M.D., vice president of clinical, medical and scientific affairs at St. Jude Medical. “Our development goal was to leverage the unique flexible tip and combine it with optimal performance and maneuverability, especially during the most challenging clinical cases. Physician experience within Europe has confirmed that we have met this goal and the FlexAbility catheter is well positioned to become an important ablation technology for electrophysiologists around the world.”
The FDA approval of the FlexAbility catheter, which received CE Mark in Europe last year, further strengthens St. Jude Medical’s fast-growing ablation technology portfolio and expands the ability of physicians to treat patients battling abnormal heart rhythms. The TactiCath™ Quartz contact-force sensing irrigated ablation catheter, approved and commercially available in Europe since 2012 and the U.S. since 2014, pioneered the ability to give physicians a real-time, objective measure of the force applied to the heart wall during a cardiac ablation procedure to treat paroxysmal atrial fibrillation (AF). The introduction of the FlexAbility catheter in the U.S. provides physicians with a best in class catheter for all their non-contact force cases. Combined, the technology offers physicians two new unique catheters that offer innovative solutions designed to improve outcomes, efficiency and productivity in electrophysiology labs worldwide.
About St. Jude Medical’s Arrhythmia Business
St. Jude
Medical's arrhythmia business, based in St. Paul, Minn., is one of the
fastest growing divisions within St. Jude Medical. A leader in
collaborating with world-renowned electrophysiologists, clinicians and
hospital administrators, St. Jude Medical develops safe and
cost-effective treatment solutions for patients in need of advanced
ablation therapies. The FlexAbility ablation catheter was developed to
be used seamlessly with St. Jude Medical’s existing portfolio of
electrophysiology products, including the EnSite™ Velocity™ System, the
Ampere™ RF Generator and the Agilis™ NxT Steerable Introducer.
For more information about St. Jude Medical’s focus on arrhythmia management, visit SJM newsroom/arrhythmias-stroke-prevention.
About St. Jude Medical
St. Jude Medical is a global medical
device manufacturer dedicated to transforming the treatment of some of
the world’s most expensive epidemic diseases. The company does this by
developing cost-effective medical technologies that save and improve
lives of patients around the world. Headquartered in St. Paul, Minn.,
St. Jude Medical has four major clinical focus areas that include
cardiac rhythm management, atrial fibrillation, cardiovascular and
neuromodulation. For more information, please visit sjm.com
or follow us on Twitter @SJM_Media.
Forward-Looking Statements
This news release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that involve risks and uncertainties. Such
forward-looking statements include the expectations, plans and prospects
for the Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made by
the Company are based upon management’s current expectations and are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. These risks and uncertainties include market conditions and
other factors beyond the Company’s control and the risk factors and
other cautionary statements described in the Company’s filings with the
SEC, including those described in the Risk Factors and Cautionary
Statements sections of the Company’s Annual Report on Form 10-K for the
fiscal year ended December 28, 2013 and Quarterly Report on Form 10-Q
for the fiscal quarter ended September 27, 2014. The Company does not
intend to update these statements and undertakes no duty to any person
to provide any such update under any circumstance.